scholarly journals Evaluation of radical surgical treatment in the management of 58 locally advanced rectal neuroendocrine neoplasms, one multicenter retrospective study

2021 ◽  
Author(s):  
Zhijie Wang ◽  
Zheng Liu ◽  
Zelin Wen ◽  
Rui Li ◽  
Ke An ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Surgical Treatment ◽  
Locally Advanced ◽  
Neuroendocrine Neoplasms

scholarly journals The Dose of Somatostatin Analogues during Pre-Surgical Treatment Is a Key Factor to Achieve Surgical Remission in Acromegaly

Endocrines ◽  
2021 ◽  
Vol 2 (3) ◽  
pp. 241-250
Author(s):  
Marta Araujo-Castro ◽  
Eider Pascual-Corrales ◽  
Héctor Pian ◽  
Ignacio Ruz-Caracuel ◽  
Alberto Acitores Cancela ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Surgical Treatment ◽  
Surgical Outcomes ◽  
Pituitary Adenomas ◽  
Somatostatin Analogues ◽  
Beneficial Effects ◽  
Key Factor ◽  
Long Acting ◽  
First Time ◽  
Endocrine Complications

Purpose: to determine whether pre-surgical treatment using long-acting somatostatin analogues (SSAs) may improve surgical outcomes in acromegaly. Methods: retrospective study of 48 patients with acromegaly operated by endoscopic transsphenoidal approach and for first time. Surgical remission was evaluated based on the 2010 criteria. Results: most patients, 83.3% (n = 40), harbored macroadenomas and 31.3% (n = 15) invasive pituitary adenomas. In this case, 14 patients were treated with lanreotide LAR and 6 with octreotide LAR, median monthly doses of 97.5 [range 60–120] and 20 [range 20–30] mg, respectively, for at least 3 months preoperatively. Presurgical variables were comparable between pre-treated and untreated patients (p > 0.05). Surgical remission was more frequent in those pre-treated with monthly doses ≥90 mg of lanreotide or ≥30 mg of octreotide than in untreated or pre-treated with lower doses (OR = 4.64, p = 0.025). However, no differences were found between pre-treated and untreated patients when lower doses were included or between those treated for longer than 6 months compared to those untreated or pre-treated for shorter than 6 months. Similarly, no differences were found either in terms of surgical or endocrine complications (OR = 0.65, p = 0.570), independently of the doses and the duration of SSA treatment (p > 0.05). Conclusions: the dose of SSAs is a key factor during pre-surgical treatment, since the beneficial effects in surgical remission were observed with monthly doses equal or higher than 90 mg of lanreotide and 30 mg of octreotide, but not with lower doses.

scholarly journals 121P Impact of HER2 low (H2L) expression on prognosis in luminal locally advanced or metastatic breast cancer (BC): A retrospective study

2021 ◽  
Vol 32 ◽  
pp. S73
Author(s):  
C. Saavedra Serrano ◽  
B. Pérez Mies ◽  
M. Gion Cortes ◽  
A. Cortes Salgado ◽  
M. Fernández Abad ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Retrospective Study ◽  
Locally Advanced ◽  
Metastatic Breast

86. Surgical treatment of locally advanced thyroid carcinoma with larynx infiltration-video presentation

2012 ◽  
Vol 38 (9) ◽  
pp. 758
Author(s):  
R. Dzodic ◽  
B. Mikic ◽  
I. Djurisic ◽  
M. Buta ◽  
M. Oruci ◽  
...  
Keyword(s):  
Surgical Treatment ◽  
Thyroid Carcinoma ◽  
Locally Advanced ◽  
Video Presentation

Use of seed i125 in the surgical treatment of locally advanced breast cancer with affection of contralateral axillary adenopathy.

2021 ◽  
Vol 32 (2) ◽  
pp. 168-170
Author(s):  
A García Reyes ◽  
P Fernández Zamora ◽  
M López-Cantarero García-Cervantes ◽  
F Del Río Lafuente ◽  
F Oliva Mompean
Keyword(s):  
Breast Cancer ◽  
Surgical Treatment ◽  
Advanced Breast Cancer ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Advanced Breast ◽  
Cáncer De Mama ◽  
Quimioterapia Neoadyuvante

Resumen El cáncer de mama localmente avanzado supone una entidad poco frecuente que requiere de un abordaje multidisciplinar. La quimioterapia neoadyuvante supone el tratamiento inicial fundamental, seguido de un tratamiento quirúrgico que suele conllevar una mastectomía, estando en debate el rescate axilar. Presentamos el caso de una paciente con cáncer de mama derecha localmente avanzado con afectación axilar derecha y afectación de un ganglio axilar contralateral, a la que el marcaje de la axila contralateral con una semilla de I125 y la demostración de respuesta axilar patológica completa, permitió la realización de BSGC de la axila izquierda, evitando una linfadenectomia axilar.

Sign in / Sign up

Export Citation Format

Share Document